Drug Trial Radar · NCT02667886
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Apr 27, 2016
Primary completion
Apr 14, 2022
Study completion Apr 14, 2022
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
Conditions
- Clear Cell Renal Cell Carcinoma
Interventions
X4P-001Drug
Continuous, oral dosing
axitinibDrug
Continuous, oral dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months)
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
Washington D.C., District of Columbia
Site not named
Jacksonville, Florida
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
New Orleans, Louisiana
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Saint Paul, Minnesota
Site not named
St Louis, Missouri
Site not named
Hackensack, New Jersey
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Toledo, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Houston, Texas
Site not named
Gyeyang-gu, Seoul, South Korea
Site not named
Seongdu, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.